Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%

Healthcare

Page 45
  1. Mar 19, 2026 · 08:05 · MBIO

    MindBio Announces Upsize to Private Placement up to $1.5 Million

    MindBio Announces Upsize to Private Placement up to $1.5 Million

    01
  2. Mar 19, 2026 · 07:30 · APS

    Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical

    Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical

    02
  3. Mar 19, 2026 · 07:30 · GUD

    Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

    Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

    03
  4. Mar 19, 2026 · 07:00 · AIAI

    NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer's Trial at AD/PD Conference

    NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer's Trial at AD/PD Conference

    04
  5. Mar 19, 2026 · 06:30 · WELL

    WELL Health Reports Record FY2025 Results; Canadian Patient Services Adjusted EBITDA Up 43% with Record Free Cash Flow

    WELL Health Reports Record FY2025 Results; Canadian Patient Services Adjusted EBITDA Up 43% with Record Free Cash Flow

    05
  6. Mar 18, 2026 · 20:20 · NVRS

    Noveris Announces Closing of Life Offering

    Noveris Announces Closing of Life Offering

    06
  7. Mar 18, 2026 · 18:23 · VHI

    VitalHub Reports Fourth Quarter 2025 Results

    VitalHub Reports Fourth Quarter 2025 Results

    07
  8. Mar 18, 2026 · 18:04 · VVTM

    VVT Med Announces Private Placement of Units

    VVT Med Announces Private Placement of Units

    08
  9. Mar 18, 2026 · 16:47 · XRTX

    XORTX Therapeutics proposes three director nominees

    XORTX Therapeutics proposes three director nominees

    09
  10. Mar 18, 2026 · 16:35 · MRVL

    Marvel Biosciences obtains U.S. patent for drug MB-204

    Marvel Biosciences obtains U.S. patent for drug MB-204

    10
  11. Mar 18, 2026 · 12:03 · CHS

    Comprehensive Healthcare to add AI features to Novus

    Comprehensive Healthcare to add AI features to Novus

    11
  12. Mar 18, 2026 · 09:39 · APPT

    UBERDOC Health Technologies Corp. to Begin Trading on the Canadian Securities Exchange Under the Symbol "APPT"

    UBERDOC Health Technologies Corp. to Begin Trading on the Canadian Securities Exchange Under the Symbol "APPT"

    12
  13. Mar 18, 2026 · 07:30 · MDNA

    Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

    Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

    13
  14. Mar 18, 2026 · 07:08 · FRX

    Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

    Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

    14
← Newer Older →